论文部分内容阅读
慢性乙肝感染是一个遍及全世界的主要健康问题,且常常演变并有发展成肝细胞癌的潜在可能。在慢性乙肝过程中,血清中HBeAg(HBeAg到抗—HBe的血清转化)和HBV DNA的自然消失常与临床和生化改善相互关联。在慢性乙肝病人治疗中,IFN的应用也可能导致了血清中HBeAg和HBVDNA消失和伴同的临床和生化改善。 在这项研究中,我们用α—干扰素治疗20例慢性乙肝病人且在治疗后跟踪了36个月。我们研究了;①对治疗的临床生化和血清学反应;②HBVDNA在治疗前、治疗期、治疗后的分子形态;③血清、肝脏HBV DNA和临床反应间的关系。 材料和方法 病人:我们研究了20例经α—干扰素治疗的慢性乙肝病人,18例男性,2例女性。年龄在28～58岁。6例为中国人。14例为出生于加拿大的白种人。
Chronic hepatitis B infection is a major health problem throughout the world and often evolves and has the potential to develop into hepatocellular carcinoma. In chronic hepatitis B, the natural elimination of HBeAg (seroconversion of HBeAg to anti-HBe) and HBV DNA in serum is often associated with clinical and biochemical improvements. In the treatment of chronic hepatitis B patients, the application of IFN may also lead to the disappearance of HBeAg and HBVDNA in serum and the accompanying clinical and biochemical improvement. In this study, we treated 20 patients with chronic hepatitis B with interferon-alpha and were followed up for 36 months after treatment. We studied the clinical and biochemical and serological responses to treatment, the molecular morphology of HBV DNA before and during treatment and after treatment, and the relationship between HBV DNA in serum and liver and the clinical response. Materials and Methods Patient: We studied 20 patients with chronic hepatitis B treated with interferon-alpha, 18 males and 2 females. The age of 28 to 58 years old. 6 cases of Chinese. Fourteen were Caucasians born in Canada.